15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering MoonLake Immunotherapeutics, 10 rate it Buy or better, 1 sit at Hold, and 2 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $5.00 to $70.00 (about 14.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $28.38 sits 43% above the current $19.89. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 9 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.91 next quarter toward $-3.37 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Moderate Buy
Strong Buy00%
Buy1077%
Hold18%
Sell215%
Strong Sell00%
Based on 13 analysts giving stock ratings to MoonLake Immunotherapeutics.
As of Jul, 10 of 13 firms rate MLTX a Buy (1 Hold, 2 Sell), the standing distribution of every covering firm's most recent active call.
MLTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.91
Range $-1.09 – $-0.62 · 8 analysts · -17% YoY
Next period, 8 analysts expect MoonLake Immunotherapeutics to earn $-0.91 a share (range $-1.09 – $-0.62), versus $-1.10 a year earlier. Full-year consensus is $-3.80, growing to $-3.37 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 8 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $19.4M next year.
Top analysts covering MoonLake Immunotherapeutics
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MLTX.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$20.00+0.6% to target
Overall win rate
52%
+ Follow
#2
Serge Belanger
Needham · Rank #83
Buy
$30.00+50.8% to target
Overall win rate
48%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$45.00+126.2% to target
Overall win rate
37%
+ Follow
#4
Brian Abrahams
RBC Capital · Rank #311
Hold
$16.00-19.6% to target
Overall win rate
25%
+ Follow
#5
Julian Harrison
BTIG
Buy
$30.00+50.8% to target
Coverage
—
+ Follow
MLTX stock forecast FAQ
What is MLTX's average 12-month price target?+
The 13 analysts with a live target average $28.38 for MoonLake Immunotherapeutics over the next 12 months, ranging from a $70.00 high to a $5.00 low.
Is MLTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 13 analyst ratings, 10 are Buy or Strong Buy, 1 are Hold, and 2 are Sell or Strong Sell.
What are the highest and lowest price targets for MLTX?+
The Street-high target is $70.00 (Clear Street), and the Street-low is $5.00 (Citigroup). The average of all 13 active targets is $28.38.
How many Wall Street analysts cover MLTX?+
13 analysts have an active rating on MoonLake Immunotherapeutics, and 13 firms carry a live 12-month price target.
Who is the most accurate analyst covering MLTX?+
Among analysts who currently cover MLTX, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $20.00 target.
What is MoonLake Immunotherapeutics's projected EPS for next quarter?+
The consensus estimate is $-0.91 per share (range $-1.09 – $-0.62) across 8 analysts. Full-year EPS is projected at $-3.80, rising to $-3.37 the following year.
How much revenue is MoonLake Immunotherapeutics expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $19.4M next year.
Have analysts been upgrading or downgrading MLTX lately?+
As of Jul, 10 of 13 firms rate MLTX a Buy (1 Hold, 2 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MLTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
